'Eml4 alk' diaporamas de présentation

Incorporating Novel Data in the Molecular Features of Lung Cancer Into the Treatment Paradigm

In association with Translational Research in Oncology. Incorporating Novel Data in the Molecular Features of Lung Cancer Into the Treatment Paradigm.

514 views • 38 slides

624 views • 26 slides

EL Kwak 1 , DR Camidge 2 , J Clark 1 , GI Shapiro 3 , RG Maki 4 ,

Clinical Activity Observed in a Phase 1 Dose-Escalation Trial of an Oral MET and ALK Inhibitor, PF-02341066. EL Kwak 1 , DR Camidge 2 , J Clark 1 , GI Shapiro 3 , RG Maki 4 , MJ Ratain 5 , B Solomon 6 , Y-J Bang 7 , S-H Ou 8 , R Salgia 5.

330 views • 23 slides

EML4-ALK translocations and crizotinib

431 views • 20 slides

Bang Y et al. Proc ASCO 2010;Abstract 3.

Clinical Activity of the Oral ALK Inhibitor, Crizotinib (PF-02341066), in Patients with ALK-Positive Non-Small Cell Lung Cancer. Bang Y et al. Proc ASCO 2010;Abstract 3. Introduction.

161 views • 14 slides

Introduction

Comparison of IHC, FISH and RT-PCR for the Detection of EML4-ALK Translocation V ariants in Non-Small C ell L ung C ancer Michelle L. Wallander 1 , Katherine B. Geiersbach 2 , Sheryl Tripp 1 and Lester J. Layfield 2

121 views • 1 slides